The Cancer Drug Development Forum (CDDF) is pleased to present our live webinar series on “AI and Big Data in Cancer Drug Development.” This series is designed to explore the transformative impact of artificial intelligence and big data on oncology. Featuring leading experts, the webinars will delve into the latest advancements and applications of AI in cancer drug discovery, development, and regulatory processes. Join us to uncover how these cutting-edge technologies are accelerating innovation, improving efficiency, and enhancing outcomes in oncology drug development.
You can learn more and rewatch the recording about the first webinar on: An introduction to the use of AI in cancer drug development and regulatory considerations here.
The second webinar in the series will be on “Using AI in assessing cancer treatment response on imaging: Project Data Sphere“ and will take place on 23 April at 17:00 CEST. This webinar will feature a key lecture given by Dr Sean Khozin (Project Data Sphere) followed by a second presentation by Dr. Christopher J. Medberry (Johnson & Johnson). A panel discussion moderated by Birgit Wolf (CDDF) and Prof. Jaap Verweij (CDDF) will follow thereafter.
WEBINAR OUTLINE
During this webinar, we will learn more about the fascinating Project Data Sphere. We will also get the chance to get an industry perspective on it. Join us for this very interesting webinar!
Agenda: (CEST time zone)
17:00 – 17:05 Introduction – Prof. Jaap Verweij (CDDF, NL)
17:05 – 17:25 Lecture by Dr Sean Khozin (Project Data Sphere, US)
17:25 – 17:35 Lecture by Dr. Christopher J. Medberry (Johnson & Johnson, NL)
17:35 – 18:00 Panel discussion – moderated by Birgit Wolf (CDDF, DE) and Prof. Jaap Verweij (CDDF, NL)
Dr Sean Khozin
Sean Khozin, MD, MPH is a physician-scientist and oncologist, recognized for his leadership in leveraging AI, machine learning, and real-world evidence to drive innovation in biomedical research, with a particular emphasis on oncology drug development.
Currently, Dr. Khozin serves as the Chief Executive Officer of the CEO Roundtable on Cancer (CEORT) and Project Data Sphere (PDS). In these roles, he directs the organizations’ public health programs in addition to pioneering initiatives focused on the development of AI foundation models in oncology. Concurrently, as the founder of Phyusion Bio and a Research Affiliate at the Massachusetts Institute of Technology (MIT), Dr. Khozin focuses on novel applications of AI and machine learning technologies to accelerate drug discovery and optimize therapeutic development strategies.
Previously, Dr. Khozin served as the Chief Executive Officer of CancerLinQ, where he led the restructuring and acquisition of the precision oncology enterprise leveraging real-world data and analytics. He also held the position of Global Head of Data Strategy and Data Science Innovation at Johnson & Johnson, implementing cutting-edge data science solutions to support the development of innovative medicines and vaccines.
Dr. Khozin’s regulatory experience includes roles as a founding member of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence and the inaugural Executive Director of FDA INFORMED, the agency’s first data science incubator that he established under special federal authorities. In this capacity, he helped shape the FDA’s stance on real-world evidence and adoption of data science methodologies across the product life cycle.
Earlier in his career, Dr. Khozin co-founded Hello Health, a technology company developing telemedicine, data visualization, and analytics solutions for optimizing patient care and clinical research. He also founded SKMD, a national network of multidisciplinary clinics in the U.S. Dr. Khozin has over a decade of experience in clinical and basic science research at the National Cancer Institute, having started his clinical work developing novel molecular profiling strategies in thoracic malignancies.
Dr. Christopher J. Medberry
Dr. Christopher J. Medberry drives innovation at the intersection of technology and healthcare as Director of Global Regulatory Affairs at J&J Innovative Medicine. With expertise in Biomedical Engineering and regulatory science earned during an FDA Fellowship, Dr. Medberry steers the successful integration of Digital Health Technologies across R&D and commercialization pipelines. Dr. Medberry empowers teams to deliver transformative healthcare solutions by navigating complex regulatory processes, ensuring they meet global standards and reach patients faster.